Scholarlink

Nonalcoholic Fatty Liver Disease (NAFLD) is one of the worldwide incidences drastically increasing and emerging continuous reasons for chronic liver disorders. It has various stages, from steatosis to severe steatohepatitis (NASH) related to hepatocellular carcinoma (HCC). Obesity and other food-related natures associated with lifestyle changes cause defective insulin secretion and dyslipidemia that establishes NAFLD. The progression of fatty liver diseases affects the metabolic environment with epigenetic and genetic factors. It is a benign class and complex LD found in 25% of patients, shifted to cirrhosis, fibrosis, HCC, liver transplant, and death. To reduce the death rate and save people from NAFLD, the medical industry requires an efficient DNA diagnosis system that can identify the earlier and late symptoms of FLD. It helps to provide accurate and appropriate treatment to save the people and avoid the progression of NAFLD. Before developing a diagnosis system, this paper provides detailed information about DNA methylation, LD, FLD, NAFLD, related DNA datasets, and abnormal patterns. It concludes that developing a model to identify NAFLD should be based on a DNA dataset, not other medical data.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Understanding Theoretical Aspects of Fatty Liver Disease Detection Using MASH, MAFLD, NAFLD, and FA DNA Datasets

  • 会议论文

  • 发表日期：

    2025年

查看全文
  • Pyla Jyothi,
  • P. Ajitha

摘要

Nonalcoholic Fatty Liver Disease (NAFLD) is one of the worldwide incidences drastically increasing and emerging continuous reasons for chronic liver disorders. It has various stages, from steatosis to severe steatohepatitis (NASH) related to hepatocellular carcinoma (HCC). Obesity and other food-related natures associated with lifestyle changes cause defective insulin secretion and dyslipidemia that establishes NAFLD. The progression of fatty liver diseases affects the metabolic environment with epigenetic and genetic factors. It is a benign class and complex LD found in 25% of patients, shifted to cirrhosis, fibrosis, HCC, liver transplant, and death. To reduce the death rate and save people from NAFLD, the medical industry requires an efficient DNA diagnosis system that can identify the earlier and late symptoms of FLD. It helps to provide accurate and appropriate treatment to save the people and avoid the progression of NAFLD. Before developing a diagnosis system, this paper provides detailed information about DNA methylation, LD, FLD, NAFLD, related DNA datasets, and abnormal patterns. It concludes that developing a model to identify NAFLD should be based on a DNA dataset, not other medical data.